Press release
Non Cystic Fibrosis Bronchiectasis Pipeline Drugs 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Non Cystic Fibrosis Bronchiectasis Treatment Landscape @ Non Cystic Fibrosis Bronchiectasis Pipeline Outlook [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Non Cystic Fibrosis Bronchiectasis Pipeline Report
* On 17 August 2025, Verona Pharma plc announced a study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
* DelveInsight's Non Cystic Fibrosis Bronchiectasis pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Non Cystic Fibrosis Bronchiectasis treatment.
* The leading Non Cystic Fibrosis Bronchiectasis Companies such as Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
* Promising Non Cystic Fibrosis Bronchiectasis Pipeline Therapies such as Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, BAY85-8501 and others.
Download for updates and be a part of the revolution in Respiratory Diseases Care @ Non Cystic Fibrosis Bronchiectasis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Non Cystic Fibrosis Bronchiectasis Emerging Drugs Profile
* Brensocatib: Insmed Incorporated
Brensocatib (INS1007 or AZD7986) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. Insmed acquired the license for the treatment from AstraZeneca in 2016. Currently, the drug is in Phase III stage of its clinical trial evaluation for the treatment of Noncystic fibrosis bronchiectasis.
* HSK31858: Haisco Pharmaceutical Group Co., Ltd.
HSK31858 tablet is an oral, potent, and highly selective dipeptidyl peptidase 1 (DPP1) small molecule inhibitor independently developed by the Haisco Pharmaceutical. The main mechanism of action is that inhibiting DPP1 can inhibit the activation of neutrophils and the release of neutrophils to the circulatory system by inhibiting the activation of neutrophil NSP enzymes. It is clinically intended to be used for the treatment of lower respiratory tract diseases caused by bronchiectasis and acute lung injury/acute respiratory distress syndrome. The drug has completed phase I clinical trials in Australia and China, and now the phase II clinical trials of the project have completed the enrollment and administration of the first subject, and the project is progressing smoothly.
* CSL 787: CSL Behring
CSL 787, is a human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Noncystic fibrosis bronchiectasis (NCFB). Currently, the drug is being developed in the Phase I stage of Clinical trial evaluation for the treatment of Noncystic fibrosis bronchiectasis.
The Non Cystic Fibrosis Bronchiectasis Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Non Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Cystic Fibrosis Bronchiectasis Treatment.
* Non Cystic Fibrosis Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Non Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Cystic Fibrosis Bronchiectasis market.
Learn more about Non Cystic Fibrosis Bronchiectasis Drugs opportunities in our groundbreaking Non Cystic Fibrosis Bronchiectasis research and development projects @ Non Cystic Fibrosis Bronchiectasis Unmet Needs [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Non Cystic Fibrosis Bronchiectasis Companies
Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
Noncystic fibrosis bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Non Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Stay informed about how we're transforming the future of Respiratory Disease @ Non Cystic Fibrosis Bronchiectasis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Non Cystic Fibrosis Bronchiectasis Pipeline Report
* Coverage- Global
* Non Cystic Fibrosis Bronchiectasis Companies- Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
* Non Cystic Fibrosis Bronchiectasis Pipeline Therapies- Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, BAY85-8501 and others.
* Non Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Non Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Non Cystic Fibrosis Bronchiectasis Pipeline on our website @ Non Cystic Fibrosis Bronchiectasis Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Noncystic fibrosis bronchiectasis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Noncystic fibrosis bronchiectasis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Brensocatib: Insmed Incorporated
* Mid Stage Products (Phase II)
* HSK31858: Haisco Pharmaceutical Group Co., Ltd.
* Early Stage Products (Phase I)
* CSL 787: CSL Behring
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Noncystic fibrosis bronchiectasis Key Companies
* Noncystic fibrosis bronchiectasis Key Products
* Noncystic fibrosis bronchiectasis- Unmet Needs
* Noncystic fibrosis bronchiectasis- Market Drivers and Barriers
* Noncystic fibrosis bronchiectasis- Future Perspectives and Conclusion
* Noncystic fibrosis bronchiectasis Analyst Views
* Noncystic fibrosis bronchiectasis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=non-cystic-fibrosis-bronchiectasis-pipeline-drugs-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non Cystic Fibrosis Bronchiectasis Pipeline Drugs 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4167121 • Views: …
More Releases from ABNewswire
North Texas Homeowners Turn to Fort Tex Metals & Roofing for Reliable Roof Repai …
Fort Tex Metals & Roofing provides certified roofing services across DFW, offering tiered options, insurance claim support, and a referral-driven reputation backed by 162 five-star Google reviews.
Storm season across the Dallas-Fort Worth region has left thousands of property owners assessing damage and weighing their options. With hail, high winds, and severe weather becoming more frequent in North Texas, the demand for dependable roofing services has surged. Fort Tex Metals &…
Long Distance Movers at Daymakers Moving and Storage Set a New Standard for Safe …
Daymakers Moving and Storage in Hudson, WI, provides full-service relocation support for cross-state moves, including packing, transport, and storage, with transparent pricing for residential and commercial clients.
The demand for professional relocation support continues to climb as more families and businesses move between states for work, lifestyle changes, and housing affordability. In Hudson, WI, one company has been quietly building a track record that speaks for itself. Daymakers Moving and Storage…
Bloomington Businesses Turn to Professional Office Movers for Smoother Transitio …
Daymakers Moving and Storage provides professional commercial relocation services in Bloomington, MN, with private trucks, real-time tracking, and climate-controlled storage for businesses across the Twin Cities.
The demand for commercial relocation support in Bloomington, MN, continues to rise as local businesses expand, downsize, or relocate. For companies navigating these changes, moving an entire operation without losing productivity has become a serious concern. That's where Daymakers Moving and Storage [https://daymakersmoving.com/bloomington-mn-movers/] steps in…
How Daymakers Moving and Storage Is Changing the Game for Commercial Relocations …
Daymakers Moving and Storage offers Roseville, MN businesses a full-service commercial relocation experience backed by 800+ five-star reviews, transparent pricing, and multi-location reach across the Twin Cities metro.
Business relocations across the Twin Cities metro are on the rise, and companies in Roseville, MN, are turning to experienced professionals to handle the heavy lifting. Daymakers Moving and Storage [https://daymakersmoving.com/roseville-mn-movers/?] has positioned itself as a reliable option for organizations that need efficient,…
More Releases for Cystic
Cystic Fibrosis Market Report-Growth with Industry Study, Detailed Analysis | Cy …
The research study contains an in detail descriptive overview and analysis of the Cystic Fibrosis Market, a summary of the market shares constituted by each component, the annual growth of each sector, and the revenue potential of the section. In addition, Cystic Fibrosis Market production and consumption data are used to determine the geographical features.
Get FREE PDF sample of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=3639856
Top Company Profile Analysis in this Report-
Cystic Fibrosis…
The Cystic Fibrosis Market to Witness Robust Growth Due to Increasing Cases of C …
Cystic fibrosis is a rare, progressive, life-threatening disease results in the formation of thick mucus that builds up in the lungs, digestive tract, and other parts of the body. If left untreated, it leads to severe digestive and respiratory problems as well as other complications such as infections and diabetes. According to the Cystic Fibrosis Foundation, more than 70,000 people are living with cystic fibrosis around the world. As the…
Cystic Fibrosis Therapeutics Market Research Reports 2017
This report studies sales (consumption) of Cystic Fibrosis Therapeutics in Europe market, especially in Germany, France, UK, Russia, Italy, Spain and Benelux, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering
Vertex Pharmaceuticals , F. Hoffmann-La Roche , AbbVie , Gilead Science , Novartis , AstraZeneca , Bayer , Celtaxsys , Pharmaxis , ProQR Therapeutics , PTC Therapeutics…
Cystic Fibrosis Market - Global Industry Analysis 2024
Cystic fibrosis (CF) is a genetic disorder that usually affects the lungs and may also affect the pancreas, kidneys, liver, and intestine. Long-term repercussions including difficulty in breathing and coughing as a result of recurrent lung infections can be seen in CF. Some of the other signs and symptoms include sinus infections, poor growth, infertility in males, fatty stool, and guild of the fingers and toes. Different individuals may have…
Cystic Fibrosis - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Cystic Fibrosis - Heat Map and Analysis to its growing collection of premium market research reports.
Cystic fibrosis (CF) is a progressive genetic condition and is the result of a patient inheriting a faulty cystic fibroses transmembrane conductance regulator (CFTR) gene from both parents. The defective CFTR genes produce faulty CFTR proteins on the body’s epithelial cells, and result in…
Cystic Fibrosis - Heat Map And Analysis
MarketResearchReports.Biz is providing you Latest Market Research report of "Cystic Fibrosis - Heat Map And Analysis".
Cystic fibrosis (CF) is a progressive genetic condition and is the result of a patient inheriting a faulty cystic fibroses transmembrane conductance regulator (CFTR) gene from both parents. The defective CFTR genes produce faulty CFTR proteins on the body?s epithelial cells, and result in the buildup of a thick and sticky mucus in the lungs…
